61924-25-2Relevant articles and documents
Process of preparing isocyanate compounds comprising non-chlorination derivatives and Composition thereof
-
Paragraph 0149-0166, (2021/10/05)
The present invention relates to a process for producing xylylene diisocyanate. The present invention relates to a process for preparing isocyanates comprising the obtained non-chlorinated derivatives. In particular, the present invention relates to an isocyanate composition comprising an unchlorinated derivative obtained by the reduction reaction and a polymerizable composition including the same.
Orally Active β-Lactam Inhibitors of Leukocyte Elastase-1. Activity of 3,3-Diethyl-2-azetidinones
Shah, Shrenik K.,Dorn, Conrad P.,Finke, Paul E.,Hale, Jeffrey J.,Hagmann, William K.,et al.
, p. 3745 - 3754 (2007/10/02)
A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic β-lactam and the mechanism of β-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE.This work led to the identification of 4--3,3-diethyl-1-carbonyl>-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE).Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model.Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays.The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.